OTIC - Otonomy, Inc.
| Previous Close | 3.5700 |
| Open | 3.5600 |
| Bid | 3.3300 x 1400 |
| Ask | 3.6800 x 800 |
| Day's Range | 3.5000 - 3.5908 |
| 52 Week Range | 1.9000 - 4.1800 |
| Volume | 66,801 |
| Avg. Volume | 155,724 |
| Market Cap | 109.777M |
| Beta (5Y Monthly) | 2.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5180 |
| Earnings Date | Nov 04, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- GlobeNewswire
Otonomy Provides Corporate and Product Pipeline Update
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. Consistent with previously stated timing, the company expects to have results for the Phase 3 trial of OTIVIDEX in Ménière’s disease in the third quarter of 2020, the Phase 1/2 trial of OTO-313 in tinnitus patients in the second quarter of 2020, and the Phase 1/2 trial of OTO-413 in patients with hearing loss in the second half of 2020. The company finished 2019 with approximately $61 million in cash, cash equivalents and short term investments and expects that its current capital is sufficient to fund operations through the three clinical trials and into 2021.
- Simply Wall St.
Should You Worry About Otonomy, Inc.'s (NASDAQ:OTIC) CEO Salary Level?
David Weber has been the CEO of Otonomy, Inc. (NASDAQ:OTIC) since 2010. This analysis aims first to contrast CEO...
- Zacks
Will Otonomy Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Otonomy.
- Benzinga
The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
- Insider Monkey
Otonomy Inc (OTIC): Are Hedge Funds Right About This Stock?
Is Otonomy Inc (NASDAQ:OTIC) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
- Zacks
Top Ranked Momentum Stocks to Buy for December 3rd
Top Ranked Momentum Stocks to Buy for December 3rd
- GlobeNewswire
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 26, 2019 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Otonomy Inc Earnings Call
- Zacks
Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene.
- GlobeNewswire
Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update
SAN DIEGO, Oct. 29, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Simply Wall St.
What Kind Of Investor Owns Most Of Otonomy, Inc. (NASDAQ:OTIC)?
Every investor in Otonomy, Inc. (NASDAQ:OTIC) should be aware of the most powerful shareholder groups. Institutions...
- Zacks
Analysts Estimate Otonomy (OTIC) to Report a Decline in Earnings: What to Look Out for
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.
- GlobeNewswire
Otonomy to Present at the Cantor Global Healthcare Conference
SAN DIEGO, Sept. 26, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), in patients with hearing loss. “Recent scientific research in the neurotology field has demonstrated that damage or loss of synaptic connections between inner ear hair cells and spiral ganglion neurons, known as cochlear synaptopathy, is involved in the hearing difficulty that many people experience in a loud environment, and that this pathology may also play a role in age-related and noise-induced hearing loss,” said Andrea Vambutas, M.D., Director for the Center of Hearing & Balance at the New York Head & Neck Institute.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Otonomy Inc Earnings Call
- GlobeNewswire
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT.
- GlobeNewswire
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
SAN DIEGO, July 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Simply Wall St.
Why Otonomy, Inc. (NASDAQ:OTIC) Is An Attractive Investment To Consider
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
- GlobeNewswire
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
SAN DIEGO, June 12, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Thomson Reuters StreetEvents
Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 Otonomy Inc Earnings Call
- Zacks
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Otonomy: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 39 cents per share. The biotechnology company posted revenue of $192,000 in the period. In the final minutes of trading on Monday, the company's shares ...
- GlobeNewswire
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial.
